NSE: JUBLINGREA · BSE: 543271 · ISIN INE0BY001018
Jubilant Ingrevia Limited stock analysis
Jubilant Ingrevia Limited ranks #1579 in the TickerSutra evidence-ranked universe with a score of 52/100 and 89% data confidence. The latest captured fundamentals show ROCE of 11.4%, quarterly sales growth of 25.3% and quarterly profit growth of 40.9%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.25×
- Strong CFO/EBITDA of 0.92×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
Risks and constraints
- Promoter pledge is 9.1% of promoter holding
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹4,949cr | ₹841cr | ₹477cr | 17.0% |
| 2023 | ₹4,773cr | ₹549cr | ₹308cr | 11.0% |
| 2024 | ₹4,136cr | ₹427cr | ₹183cr | 10.0% |
| 2025 | ₹4,178cr | ₹519cr | ₹251cr | 12.0% |
| 2026 | ₹4,388cr | ₹568cr | ₹278cr | 13.0% |
| TTM | ₹4,651cr | ₹624cr | ₹309cr | 13.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Jubilant Ingrevia Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineRecord Date UpdatesNSE · 25 Sept 2026Record Date Updates
RoutineUpdatesNSE · 25 Sept 2026Jubilant Ingrevia Limited has informed the Exchange regarding 'Intimation of Record Date for Maturity of Commercial Paper'.
RoutineJubilant Ingrevia Ltd - 543271 - Intimation Of Record Date For Maturity Of Commercial PaperBSE · 25 Sept 2026Intimation of Record Date for maturity of Commercial Paper
MANAGEMENT COMMENTARY
Signals from filed documents
In choline, we maintained our domestic market position and continued to witness healthy demand from Europe alongside improved customer realizations. The premixes business also performed well with volume growth and a favorable product mix driving margin expansion. In Chemical Intermediates business, it saw a strong rebound in Q1 on the back of robust demand and price escalations.
In Chemical Intermediates business, it saw a strong rebound in Q1 on the back of robust demand and price escalations. Revenue in the segment grew to INR524 crore, up 38% year-on-year and 21% quarter-on-quarter, driven by strong volume growth and improved realizations, supported by higher input cost pass-throughs. EBITDA for the segment stood at INR57 crore, up 240% year-on-year and 163% quarter-on-quarter, driven by
So would that imply that the segment ex of the agro CDMO contract would have seen some revenue decline? And I mean, any pricing or margin pressures there? Or was the CDMO revenue looking lower than expected there.
We witnessed a stable momentum in the agrochemicals during the quarter, with demand trends showing encouraging signs of recovery across key segments. Healthy export visibility and improving market dynamics have supported recent price increases. The Nutrition and Personal Care market witnessed healthy growth during the quarter, led by higher realizations for niacinamide and choline.
Our pyridine and picoline business delivered steady volumes during the quarter. Despite some pricing pressure in pyridine, cost optimization initiatives helped sustain a healthy performance. Our Fine Chemicals business delivered strong momentum during the quarter.
We are encouraged by the progress of our Pinnacle journey, which is increasingly reflected in our performance through strong revenue and EBITDA growth and a stronger opportunity pipeline. Supported by sustained volume growth and a firmer pricing, we remain confident of continuing our growth momentum. FY 2027, we expect growth to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…